AKUMS — Akums Drugs and Pharmaceuticals Income Statement
0.000.00%
- IN₹148.05bn
- IN₹150.94bn
- IN₹41.78bn
Annual income statement for Akums Drugs and Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS |
Standards: | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 27,226 | 36,719 | 36,548 | 41,782 |
Cost of Revenue | ||||
Gross Profit | 9,304 | 11,838 | 11,999 | 14,352 |
Selling / General / Administrative Expenses | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 25,106 | 33,724 | 35,375 | 38,478 |
Operating Profit | 2,120 | 2,995 | 1,174 | 3,304 |
Gain / Loss on Sale of Assets | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | 1,723 | -1,932 | 1,503 | -453 |
Provision for Income Taxes | ||||
Net Income After Taxes | 1,234 | -2,509 | 978 | 7.9 |
Minority Interest | ||||
Net Income Before Extraordinary Items | ||||
Net Income | 1,227 | -2,525 | 949 | -40.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | 1,227 | -2,525 | 949 | -40.4 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | 8.27 | -15.5 | 8.83 | 0.826 |
Dividends per Share |